Skip to main content
Premium Trial:

Request an Annual Quote

Roche Receives FDA EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test

NEW YORK – Roche announced on Friday that its RT-PCR-based Cobas SARS-CoV-2 nucleic acid test for use on the Cobas Liat system has received Emergency Use Authorization from the US Food and Drug Administration.

The test can return results in 20 minutes and can be used for screening both asymptomatic and symptomatic people. It is the first molecular, point-of-care test that has received EUA for detecting SARS-CoV-2 in asymptomatic people, the company said in a statement.

Roche said the test is for use at a variety of POC settings including emergency and primary care, physician offices, and screening locations. A Roche spokesperson said the price of the test usually depends on the specific contract with users.

The test will be available in the US and in countries accepting the CE mark in July, Roche said.

In February, Roche's Cobas Influenza A/B & RSV nucleic acid test received 510(k) clearance from the FDA for use on the Liat system. Last September, the firm received EUA for its Cobas SARS-CoV-2 & Influenza A/B test on the Liat system.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.